stoxline Quote Chart Rank Option Currency Glossary
Dynavax Technologies Corporation (DVAX)
11.5  0.11 (0.97%)    05-28 16:00
Open: 11.26
High: 11.52
Volume: 2,203,760
Pre. Close: 11.39
Low: 11.26
Market Cap: 1,505(M)
Technical analysis
2024-05-28 4:21:56 PM
Short term     
Mid term     
Targets 6-month :  14.1 1-year :  16.47
Resists First :  12.07 Second :  14.1
Pivot price 11.33
Supports First :  11.09 Second :  10.47
MAs MA(5) :  11.61 MA(20) :  11.41
MA(100) :  12.42 MA(250) :  13.22
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  72.3 D(3) :  76.7
RSI RSI(14): 49.8
52-week High :  15.14 Low :  10.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ DVAX ] has closed below upper band by 38.0%. Bollinger Bands are 5.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.53 - 11.58 11.58 - 11.64
Low: 11.13 - 11.19 11.19 - 11.25
Close: 11.4 - 11.5 11.5 - 11.59
Company Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Headline News

Tue, 28 May 2024
Dimensional Fund Advisors LP Acquires 293,337 Shares of Dynavax Technologies Co. (NASDAQ:DVAX) - MarketBeat

Sun, 26 May 2024
Dynavax Technologies (NASDAQ:DVAX) Stock Price Down 3.4% - Defense World

Fri, 24 May 2024
Is Dynavax Technologies Corporation a Buy? - Yahoo Singapore News

Wed, 22 May 2024
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S - Simply Wall St

Tue, 14 May 2024
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in ... - PR Newswire

Sat, 11 May 2024
Analysts Are Updating Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates After Its First-Quarter ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 131 (M)
Shares Float 123 (M)
Held by Insiders 0.3 (%)
Held by Institutions 97.9 (%)
Shares Short 19,620 (K)
Shares Short P.Month 17,970 (K)
Stock Financials
EPS -0.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.75
Profit Margin 3.9 %
Operating Margin -38.2 %
Return on Assets (ttm) -1.4 %
Return on Equity (ttm) 1.5 %
Qtrly Rev. Growth 8.1 %
Gross Profit (p.s.) 0
Sales Per Share 1.8
EBITDA (p.s.) -0.13
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -230
PEG Ratio 0
Price to Book value 2.42
Price to Sales 6.37
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android